2 Celebrex. NSAIDS affect two enzymes, COX-1 and COX-2, while the COX-2 inhibitors were meant to decrease side-effects by targeting only COX-2, which is involved in inflammation. Their targeted effects on inflammation may also help them prevent cancer, said Dr. Oleg Glebov of the U.S. National Cancer Institute. Glebov's team found that Celebrex, known generically as celecoxib, alters a specific "signature" set of 173 genes in the colons of patients at high risk for a hereditary form of colon cancer. Many of the genes are involved in immune and inflammatory response, he told a meeting in Anaheim, California, of the American Association for Cancer Research. "We found that treatment of patients with celecoxib led to changes in more than 1,400 genes in the healthy colon," Glebov said in a statement. "Of those genes, a specific set of 173 forms a signature portfolio that accurately identifies the colonic biopsies from patients taking ... celecoxib." --More 2327 Local Time 2027 GMT
